AZD3293 Thorough QT study in healthy male volunteers - AZD3293TQT

Study identifier:D5010C00008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (moxifloxacin) as a Positive Control, in Healthy Male Subjects

Medical condition

Alzheimer's disease

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3293, Placebo, Moxifloxacin

Sex

Male

Actual Enrollment

52

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Jan 2014
Primary Completion Date: 01 May 2014
Study Completion Date: 01 May 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jul 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria